RE:CG Oncology phase 3 results impossible for TLT to beat?cancerman24 wrote: 75.7% complete response rate at any time in phase 3. Announced Nov 30 2023 so may all know about it already.
Not bashing, just asking.
COMPLETELY FALSE!
In this link...
https://clinicaltrials.gov/study/NCT04387461 Under '' Participation Criteria''...There is a blue box ''
Show More'' Inside you will find the ''key Exclusion Criteria''.
The two most interesting are ...
1) Clinically significant or active cardiac disease(older patients are more likely to have cardiac disease).
2)Active autoimmune disease(older patients are also more likely to have autoimmune disease).
In this link...
https://autoimmune.org/disease-information/ Over 100 autoimmune diseases, that is a huge exclusion criteria, TLT-Ruvidar doesn't have this kind of exclusion criteria.
TLT-Ruvidar can treat 100% of patients(and the worst of the worst patients).
Once again, if TLT-Ruvidar had the same exclusion criteria as CG Oncology, TLT-Ruvidar CR% would be well over 80%CR.
Question? Why is it that more and more posters are coming on with these
phony TLT competitors? Until proven otherwise TLT-Ruvidar is by far superior to anything out there.
Have a nice weekend.